Zircon Kidney Cancer Imaging Study completes Enrollment
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Distribution Agreement with Isologic for Illuccix in Canada
- Expansion of Partnership with RefleXion for Prostate Cancer
- Telix receives AUD$17.25 million R&D tax refund
- Leadership changes including Darren Smith appointment as CFO
- Illuccix Reimbursement Milestone and Launch Updates
Later from Telix Pharmaceuticals
- Kevin Richardson appointed as CEO, Telix Americas
- Appendix 4C and Activities Report for June 2022 Quarter
- APAC Regulatory Progress Prostate and Kidney Cancer Imaging
- Grand Pharmaceutical Groups investment in Telix
- Appendix 4D - Results for announcement to the market
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals